FY2026 EPS Estimate for Atyr PHARMA Reduced by Analyst

Atyr PHARMA INC (NASDAQ:ATYR) – Research analysts at HC Wainwright cut their FY2026 EPS estimates for Atyr PHARMA in a research note issued on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.66) per share for the year, down from their previous forecast of ($0.53). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Atyr PHARMA’s FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.50 EPS.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Finally, Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Atyr PHARMA has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Stock Up 7.8 %

ATYR stock opened at $3.60 on Friday. The stock has a market capitalization of $319.89 million, a P/E ratio of -3.83 and a beta of 0.95. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $3.29 and a 200-day moving average price of $3.39. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05.

Institutional Trading of Atyr PHARMA

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Group One Trading LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $26,000. Alterna Wealth Management Inc. acquired a new position in shares of Atyr PHARMA in the fourth quarter worth approximately $36,000. Victory Capital Management Inc. bought a new stake in Atyr PHARMA in the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. acquired a new stake in Atyr PHARMA during the 4th quarter valued at approximately $39,000. Finally, XTX Topco Ltd bought a new position in Atyr PHARMA during the 4th quarter worth approximately $40,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.